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Heterogeneity in clinical research data quality monitoring: a national survey
Abstract
Introduction Clinical research is vital in the discovery of new medical knowledge and reducing disease
risk in humans. In clinical research poor data quality is one of the major problems, affecting data integrity
and the generalisability of the research findings. To achieve high quality data, guidance needs to be
provided to clinical studies on the collection, processing and handling of data. However, clinical trials are
implementing ad hoc, pragmatic approaches to ensure data quality. This study aims to explore the
procedures for ensuring data quality in Australian clinical research studies. Material and methods We
conducted a national cross-sectional, mixed-mode multi-contact (postal letter and e-mail) web-based
survey of clinical researchers associated with clinical studies listed on the Australian and New Zealand
Clinical Trials Registry. Results Of the 3689 clinical studies contacted, 589 (16%) responded, 570 (97%)
consented and 441 (77%) completed the survey. 67% clinical studies reported following national and/or
international guidelines for data monitoring, with the National Statement (86%) and Good Clinical Practice
Guidelines (55%) most common. Source data were most likely to be recorded on one instrument (46%), of
which paper (77%) being most common. 46.4% studies did not use data management software and 55%
monitored data via traditional approaches (e.g. source data verification). Training on data quality was only
provided to less than half of the staff responsible for data entry (43.9%) and data monitoring (37.5%).
Regression analysis on 179 (33%) respondents found a borderline significant association between
intervention trials and a definition for protocol deviation and/or violation (odds 3.065, p = 0.096). This may
suggest when clinical trials are provided with additional guidance and resources, they are more likely to
implement required procedures. Statistical strength of the full regression model was not significant χ2
(13, 179) = 15.827, p = 0.259. Conclusion Small single-site academic clinical studies implemented ad hoc
procedures to ensure data quality. Education and training are required to promote standardised practices
to ensure data quality in small scale clinical trials.
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Abstract
Introduction: Clinical research is vital in the discovery of new medical knowledge and reducing
disease risk in humans. In clinical research poor data quality is one of the major problems, affecting
data integrity and the generalisability of the research findings. To achieve high quality data,
guidance needs to be provided to clinical studies on the collection, processing and handling of data.
However, clinical trials are implementing ad hoc, pragmatic approaches to ensure data quality. This
study aims to explore the procedures for ensuring data quality in Australian clinical research
studies.
Material and methods: We conducted a national cross-sectional, mixed-mode multi-contact
(postal letter and e-mail) web-based survey of clinical researchers associated with clinical studies
listed on the Australian and New Zealand Clinical Trials Registry.
Results: Of the 3689 clinical studies contacted, 589 (16%) responded, 570 (97%) consented and
441 (77%) completed the survey. 67% clinical studies reported following national and/or
international guidelines for data monitoring, with the National Statement (86%) and Good Clinical
Practice Guidelines (55%) most common. Source data were most likely to be recorded on one
instrument (46%), of which paper (77%) being most common. 46.4% studies did not use data
management software and 55% monitored data via traditional approaches (e.g. source data
verification). Training on data quality was only provided to less than half of the staff responsible for
data entry (43.9%) and data monitoring (37.5%). Regression analysis on 179 (33%) respondents
found a borderline significant association between intervention trials and a definition for protocol
deviation and/or violation (odds 3.065, p=0.096). This may suggest when clinical trials are provided
with additional guidance and resources, they are more likely to implement required procedures.
Statistical strength of the full regression model was not significant χ2 (13, 179) = 15.827, p=0.259.
Conclusion: Small single-site academic clinical studies implemented ad hoc procedures to ensure
data quality. Education and training are required to promote standardised practices to ensure data
quality in small scale clinical trials.
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1. Introduction
Clinical research is vital in the discovery of new treatments, prevention, diagnosis/screening and
reducing the risk of disease in humans[1]. In clinical research poor data quality is one of the major
problems, seriously affecting data integrity and the generalisability of the research findings[2, 3].
Therefore, minimising poor quality data is crucial for clinical research to produce accurate and
reliable evidence to improve patient care. Best practice to ensure data quality is preventing errors
from happening rather than retrospectively finding and fixing errors[4]. To achieve this, guidance
can be provided to clinical research studies on the collection, processing and handling of data.
However, previous research identifies current international and national clinical data quality
guidelines lack uniformity creating confusion within the research community[5]. Thus, there is a
need to ensure clinical research is carried out in accordance with standardised procedures that meet
known quality guidelines.

The International Conference on Harmonization (ICH) guideline for Good Clinical Practice (GCP)
E6(R2) is an ethical and scientific quality standard for designing, conducting, recording and
reporting trials that involve human participants[6]. The guideline states, “quality control should be
applied to each stage of data handling to ensure that all data are reliable and have been processed
correctly” [pg.22]. These guidelines are not specific about the amount of monitoring needed to
ensure quality and give flexibility in their interpretation[7, 8]. Concerns regarding broad guidelines
were identified amongst clinical research centres responding to a survey of data quality
management in Europe[9]. The three key findings of this survey are: firstly, heterogeneity in data
management exists; secondly, freely available clinical data management guidelines are limited; and
thirdly, 50% of centres did not comply with guidelines, including GCP for independent validation
by an external auditor[9]. It is evident that a standardised, more specific approach needs to be
adopted for monitoring data quality in clinical research. In accordance with this notion, a survey
conducted by the Clinical Trials Transformation Initiative (CTTI) in the United States also found
that there is heterogeneity within and between organizational monitoring practices across academic
government, clinical research organizations and industry[10]. This has led to a quest by many
researchers for new avenues to monitor data quality in clinical research settings.

The importance of data quality is well established within the clinical research community[5, 11, 12]
and the need for training has been identified[13-15]. For instance, providing training and
implementing testing to all key clinical trial staff in GCP, protocols and standard operating
procedures (SOPs) is vital for improving the clinical research process[16]. Unfortunately, only a
few data management training programs have been proposed and are specific to the nursing

literature[17, 18]. Recently, Read[19] published a case study that highlighted a workshop training
series to educate clinical researchers on best practice with data management, including core
competencies in data quality maintenance. However, none of these programs explicitly emphasize
the importance of monitoring to ensure data quality. In an effort to overcome the lack of evidence,
further empirical research is needed to identify standardised guidelines for clinical research data
quality monitoring and relevant training programs.

Our initial study identified developing and maintaining data management is a challenge for clinical
trials[5]. We found clinical trials implemented ad hoc, pragmatic approaches to ensure data quality
and only 50% reported having a data management plan. Thus, the current study aimed to explore in
more detail, the procedures that are implemented for ensuring data quality in Australian clinical
studies. We defined the objective to acquire an improved understanding from clinical researchers on
how data is defined, collected, processed and handled, and any education and training related to
data quality in this process. This will lead to a new body of knowledge upon which to develop a
data quality monitoring framework.

2. Material and Methods
2.1. Planning
A mixed mode multi-contact national survey design was implemented to achieve high responses by
ensuring broad contact with the target population and providing them with the opportunity to
respond. In order to reduce total survey error, all four sources of error (coverage, sampling, nonresponse and measurement error) were simultaneously controlled by applying a tailored holistic
approach informed by the principles proposed by Dillman et al.[20]. Social exchange theory was
applied to decrease cost, establish trust and increase the benefits for survey respondents[21-23].
Overall, the survey design was tailored to the population (clinical researchers), situation (Australia)
and topic (data quality).

2.2. Setting
Clinical studies listed on the Australian and New Zealand Clinical Trials Registry (ANZCTR)[24]
as of 1st March 2018 were invited to participate in a cross-sectional survey. The ANZCTR database
is an online registry of clinical studies being undertaken in Australia, New Zealand and elsewhere.
An advance search of the ANZCTR database was completed with the following inclusion criteria:
intervention and observation trials; randomised and non-randomised trials; recruitment status either
‘recruiting’ or ‘active, not recruiting’; all gender; all age groups; ethics approved; both healthy and
non-healthy volunteers; and recruitment country being Australia. Persons listed on the ANZCTR

registry as the contact for scientific queries for each clinical study were asked to complete the
survey. Sampling error was reduced by inviting all clinical studies that met the inclusion criteria.
However, as it is not a legal requirement for clinical studies in Australia to be listed on the registry,
it is inevitable to miss those not on the registry.

To avoid the potential risk of bias, clinical studies with affiliation to the University of Wollongong
(UoW), the organisation where the researchers were employed, were excluded from the study. Also
excluded were clinical studies with international contact details so as to minimise the influence of
different national regulations/guidelines for conducting data monitoring. Those who did not wish to
participate were provided with an option to withdraw and provide an optional reason. Informed tacit
consent was given by completion of the online survey questionnaire form. Ethics approval was
obtained from the UoW Human Research Ethics Committee (HE16/131).

2.3. Question design and development
The design and development of the survey followed the Checklist for Reporting Results of Internet
E-Surveys (CHERRIES)[25, 26]. A 46 item self-administed semi-quantitative closed survey design
was developed and informed by our feasibility study[5]. Adaptive questioning was applied to 14
items branching the total number of questions depending on individual survey responses. Answers
to all items were voluntary. Respondents were provided with the option to skip or leave question
items blank, or choose non-responses, such as “not applicable” or “don’t know”.

The survey included seven sections: respondent demographics, clinical study demographics, data
definition, data collection, data processing, data representation and education and training. REDCap
(Research Electronic Data Capture), a secure, web-based application designed to support data
capture for research studies[27], was used to design the survey, collect and manage data. Construct
validation, including wording, structure, order and grouping of questions were evaluated by a
convenience sample of three UoW researchers. Once consensus on the design of questions was
reached further feedback was sought through think-aloud cognitive interviews[28] with five UoW
clinical researchers and based on two types of theories. First, how individuals respond to survey
questions was based on the psychological perspective promoted by the Cognitive Aspects of Survey
Methodology (CASM) viewpoint by Tourangeau’s four-stage cognitive model[29]. Second, the
cognitive interview as a means to test survey questions (methodology) was based on Ericsson and
Simon’s think-aloud interview theoretical basis[30, 31]. The cognitive interviews used a descriptive
approach[32] and aimed to reduce measurement error by gaining a better understanding of how
respondents understand and interpret the survey items, visual design, presentation and navigation

problems. Participation in the face-to-face audio recorded interview was voluntary and each
participant returned a signed consent form prior to commencing the interview.

2.4. Survey administration
The web-based survey in order to reduce coverage error, contacted respondents via two modes of
communication, postal delivery and e-mail, which Millar and Dillman[33] suggest can encourage
responses. The initial postal letter was sent on 26th March 2018 and followed by three e-mail
reminders over an 11-week period. The postal letter contained a link to the REDCap online survey
login and included an individual access code. The email reminders included a personal Uniform
Resource Locator (URL) link that allowed the respondent to automatically log into the survey for
convenience. To increase the likelihood of responses and simultaneously reduce nonresponse error
multiple contact attempts were made which varied in contact timing. Each clinical study was
provided with a de-identified participant code to ensure anonymity. Respondents using their unique
survey code and/or URL were able to log back into the survey to review and edit items prior to final
submission and survey closing date. If surveys were incomplete the most recent data entry was
saved for data analysis.

2.5. Data analysis
Incomplete surveys were included in the analysis to respect all respondents’ contributions and
reduce the bias of topic salience. Data was analysed with IBM SPSS software (IBM Corp. Released
2017. IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY: IBM Corp.). Descriptive
statistics summarised the characteristics of respondents, clinical study demographics and the
aggregated responses to survey items. For ‘select all that apply’ survey items the multiple response
set was used in SPSS using a dichotomies scale. Free text responses were analysed using deductive
content analysis[34].

Univariate analysis was performed to determine the potential association between data quality
monitoring variables and clinical study type using chi-square analysis. Any independent variables
(predictors) which achieved significance at p<0.2[35] were considered for inclusion in the
multivariate analysis. The dependent variable was an intervention (clinical) trial or not (i.e. an
observational study). All covariates included in the model are listed in Table 4. The cross-sectional
associations between clinical study demographics, data collection setting and data quality
monitoring procedures and those classified as an intervention (clinical) trial were analysed using
three methods - forced entry, forward and backward likelihood ratio (LR) stepwise - logistic
regression (p<0.05). This decision was made in accordance with the recommendations for data

analysis and research without precedence, i.e., to base a hypothesis for testing[36, 37]. Forced entry
method is the preferred method[38], forward and backward stepwise logistic regression are reported
in Supplementary data 5 and Supplementary data 6 respectively. In all three methods, the
dependent variable and the independent variables (met the p<0.2 criteria) (see footnote Table 4;
Supplementary data 5, Table 1; and Supplementary data 6, Table 1) that were considered were
identical. The probability for the forwards stepwise method was set at 0.5 and the backwards
stepwise method set at 0.1[36, 37]. Survey responses ‘not applicable’ and ‘don’t know’ were coded
as missing and removed from the regression analysis. The survey question, ‘Does the clinical study
involve staff in developing case report forms (CRF)s?’ was exempt from this; instead, ‘not
applicable’ answers were included considering the possibility of a student, volunteer and/or single
project lead/person developed the CRFs.

3. Results
Initial postal letter invitations were sent to 3845 of the 3999 clinical studies identified in the
ANZCTR registry (Figure 1). 146 respondents could not be contacted as the postal letter was
returned to the sender (RTS) and all three follow-up messages were bounced back with an error
message. Therefore, only 3689 respondents received the invitation to complete the survey. 589
viewed the initial survey page (16% view rate). 570 agreed to participate (96.8% participation rate).
Only 547 responses were included in analysis as 23 empty responses were excluded. Finally, 441
responses were complete (77.4% completion rate). Survey respondents were more likely to be
female, have a doctoral degree, employed for a duration of 0-4 years and on a continuing
appointment (Table 1). The deidentified data set (n=547) and the instructions for access have been
made public at https://github.com/lah993/DQ_national_survey in accordance with the Creative
Commons Attribution 4.0 International license[39].

Figure 1: Survey invitation flow diagram.

Table 1: Survey respondents’ demographic characteristics (n=547).
Characteristics
Gender
Female
Male
Prefer not to disclose
Prefer to self-describe
Missing
Highest level of
Doctoral degree
education
Masters/Postgraduate degree
Bachelor degree (including Honours)
Did not complete high school
Missing
Duration of
0-4
current
5-9.9
employment,
10-14.9
nearest half year
15-24.9
25+
Missing
Appointment
Student
(current job or
Casual
position)
Continuing
Visiting / Honorary Fellow
Fixed-term contract, nearest half yeara (years)
<1
1-1.9
2-2.9
3-3.9
4-4.9
≥5
Missing
Missing
a

n (%)
332 (60.7)
206 (37.7)
6 (1.1)
1 (0.2)
2 (0.4)
347 (63.4)
115 (21.0)
84 (15.4)
1 (0.2)
0 (0)
157 (28.7)
140 (25.6)
102 (18.6)
93 (17.0)
35 (6.4)
20 (3.7)
23 (4.2)
13 (2.4)
292 (53.4)
15 (2.7)
198 (36.2)
25 (12.6)
66 (33.3)
17 (8.6)
22 (11.1)
24 (12.1)
44 (22.2)
0 (0)
6 (1.1)

specified time or ascertainable period

Characteristics of the clinical studies described by the survey respondents are provided in Table 2.
The majority of survey respondents were associated with clinical studies that were administered
from academic (university) organisations, were an interventional clinical trial, phase IV and singlesite. Further, clinical studies mostly collected data from hospital setting, targeted 100-499
participants for baseline enrolment and did not employ a data monitor or data manager (Table 2).

Table 2: Survey respondents associated clinical study demographic characteristics (n=547).
Characteristics
Percent of Cases
n (%)
(%)
Organisation that
Academic (university)
317 (47.4)
59.7
administers the studya,b
Hospital
190 (28.4)
35.8
Independent research institute 66 (9.9)
12.4
Cooperative
29 (4.3)
5.5
group/consortium
Non-government organization 18 (2.7)
3.4
Government
17 (2.5)
3.2
Industry
8 (1.2)
1.5
Not applicable
2 (0.3)
0.4
Other
6 (0.9)
1.1
Missing
16 (2.4)
2.9
Number of health
0
4 (0.7)
professionals’ part of the
1
170 (31.1)
clinical study team
2
162 (29.6)
3
110 (20.1)
>4
78 (14.3)
Missing
23 (4.2)
Study type
Intervention (clinical trial)
451 (82.4)
Observation
80 (14.6)
Missing
16 (2.9)
Intervention typec
Treatment
314 (69.6)
Prevention
83 (18.4)
Quality of life
20 (3.7)
Screening
12 (2.7)
Epidemiological
8 (1.8)
Diagnostic
8 (1.8)
Genetic
1 (0.2)
Missing
5 (1.1)
Phase type
Phase 0 (Exploratory)
51 (9.3)
Phase I
67 (12.2)
Phase II
92 (16.8)
Phase III
94 (17.2)
Phase IV
69 (12.6)
Don’t know
10 (1.8)
Not applicable
144 (26.3)
Missing
20 (3.7)
Number of clinical study
1
296 (54.1)
trial sites
2-4
116 (21.2)
5-9
46 (8.4)
10-19
32 (5.9)
>20
39 (7.1)
Missing
18 (3.3)
Multi-site studies being Yes
53 (22.7)
part of an international
No
179 (76.8)
studyd
Missing
1 (0.4)
Data collection settinga,e
Hospital
321 (48.8)
60.9
University
83 (12.6)
15.7
Private practice
49 (7.4)
9.3
Health centre
48 (7.3)
9.1

Participants targeted for
baseline enrolment

Employ a data monitor or
data manager

Independent research institute
In-home care
Other
Missing
<20
20-99
100-499
>500
Missing
Yes
No
Not applicable
Don’t know
Missing

46 (7.0)
23 (3.5)
68 (10.3
20 (3.0)
49 (9.0)
192 (35.1)
203 (37.1)
82 (15.0)
21 (3.8)
250 (45.7)
255 (46.6)
17 (3.1)
6 (1.1)
19 (3.5)

8.7
4.4
12.9
3.7

a Multiple

response question (select all that apply)
(%) =669 (100.0)
c Intervention type, n=451.
d Part of an international study, n=233.
e Total n (%) =658 (100.0)
b Total n

Table 3 shows survey responses regarding data definition, collection, processing and representation,
and education and training on data quality. The majority of respondents (366, 66.9%) reported that
the clinical study followed national and/or international regulations, guidelines and/or standards
(Table 3). Of those who responded ‘yes’ and ‘don’t know’1, n=422 (77.1%) to following
regulations, guidelines and/or standards the National Statement on Ethical Conduct and Research
(86.0%) was most commonly used. This was followed by the Good Clinical Practice (GCP)
guideline (54.5%) and the Australian Clinical Trials Handbook (33.6%) (Supplementary data 1).
The most common (46.4%) response to the question about the recording medium for source data
was a single data capture instrument. The major recording instrument was paper (77.0%) and least
was mobile or tablet application (10.4%) (Supplementary data 2). Just under half (46.4%) of the
respondents reported not using any clinical data management software to store data. Of those who
did (35.3%), the majority (93.3%) utilised a single application (93.3%) (Table 3); REDCap data
management software was most common (17.6%) (Supplementary data 2). At the time of the
survey, 418 (76.4%) respondents answered that more than one monitoring method was applied to
the clinical study. With statistical techniques (64.5%), logic, range and consistency checks (63.6%)
and source data verification (SDV) (55.0%) most commonly applied to audit and monitor data.
Only 48 (8.8%) of respondents reported a set error acceptance level; of which 28 (58.3%) reported
the level ranging from 0-10% (mean 4.6 ± 2.8 SD). Further, only 72 (13.2%) clinical studies
reported generating data quality and consistency reports. The personnel responsible for reviewing
these reports varied, ranging from the chief investigator (63.9%), senior staff management (50.0%)
Survey respondents who selected ‘don’t know’ were also presented with the same list of regulations, guidelines and/or
standards as those selected ‘Yes’.
1

and data entry staff (43.1%) (Supplementary data 3). In total, two-thirds (66.7%) of respondents
answered that more than one person reviewed these reports. Less than half of the respondents
answered that training and/or development devoted to data quality was provided to the primary
person(s) responsible for data entry (240, 43.9%) and data monitoring (205, 37.5%) (Table 3). The
most common training component for both data entry staff (79.1%) and data monitors (80.8%) was
in protocol procedures (Supplementary data 4). Similarly, respondents answered that training in
more than one area was received by data entry (205, 85.4%) and data monitoring (176, 85.9%) staff.

Table 3: Data quality monitoring, education and training on data quality (n=547).
Item
Not
Don’t
Missing
Yes
No
applicable know
data
n (%)
n (%)
n (%)
n (%)
n (%)
Data dictionary
Does the clinical study…
have a data dictionary?
262 (47.9) 190 (34.7) 44 (8.0)
23 (4.2)
28 (5.1)
involve staff in developing CRFs?
289 (52.8) 135 (24.7) 76 (13.9)
18 (3.3)
29 (5.3)
have a definition for protocol
349 (63.8) 117 (21.4) 42 (7.7)
9 (1.6)
30 (5.5)
deviation and/or violation?
have a data quality monitoring plan
or SOP for quality assurance and
343 (62.7) 136 (24.9) 22 (4.0)
13 (2.4)
33 (6.0)
quality control?
outsource data monitoring to another
27 (4.9)
454 (83.0) 27 (4.9)
5 (0.9)
34 (6.2)
company?
follow national and international
regulations, guidelines and/or
366 (66.9) 59 (10.8)
34 (6.2)
56 (10.2) 32 (5.9)
standards for data monitoring?
Data collection and storage
Does the clinical study…
have a standard operating procedure
399 (72.9) 85 (15.5)
10 (18.)
10 (1.8)
43 (7.9)
specifically for data collection?
implement procedures to overcome
missing values in the process of data 242 (44.2) 153 (28.0) 60 (11.0)
49 (9.0)
43 (7.9)
collection?
Number of data capture instruments used to record source data?
1
254 (46.4)
2
149 (27.2)
3
68 (12.4)
4+
37 (6.8)
Missing
39 (7.1)
Does the clinical study use a clinical
193 (35.3) 254 (46.4) 26 (4.8)
22 (4.0)
52 (9.5)
data management tool to store data?
Number of tools used to store data?a
1
180 (93.3)
2
13 (2.4)
Missing
0 (0)
Data processing
Does the research team of the clinical study complete any of the following data monitoring procedures?
Statistical techniques
353 (64.5) 69 (12.6)
29 (5.3)
20 (3.7)
76 (13.9)
Logic, range and consistency checks 348 (63.6) 77 (14.1)
37 (6.8)
18 (3.3)
67 (12.2)
Source data verification
301 (55.0) 105 (19.2) 48 (8.8)
23 (4.2)
70 (12.8)
Onsite monitoring
259 (47.3) 148 (27.1) 46 (8.4)
20 (3.7)
74 (13.5)
Double data entry
190 (34.7) 224 (41.0) 43 (7.9)
17 (3.1)
73 (13.3)
Centralised monitoring
150 (27.4) 200 (36.6) 87 (15.9)
24 (4.4)
86 (15.7)
Remote monitoring
86 (15.7)
258 (47.2) 98 (17.9)
17 (3.1)
88 (16.1)
Risked-based targeted monitoring
58 (10.6)
247 (45.2) 102 (18.6) 50 (9.1)
90 (16.5)
Risked-based triggered monitoring
56 (10.2)
244 (44.6) 106 (19.4) 50 (9.1)
91 (16.6)
Other
9 (1.6)
141 (25.8) 88 (16.1)
31 (5.7)
278 (50.8)
Data representation
Does the clinical study…
have an error acceptance level?
48 (8.8)
222 (40.6) 92 (16.8)
94 (17.2) 91 (16.6)

If yes, and the error rate is found
to be higher than the approved
acceptance level, does your
25 (52.1)
7 (14.6)
11 (22.9)
2 (4.2)
organisation implement further
follow-up monitoring?b
have a standard equation and/or
50 (9.1)
219 (40.0) 88 (16.1)
89 (16.3)
method used to calculate error?
have data quality and consistency
72 (13.2)
229 (41.9) 78 (14.3)
67 (12.2)
reports generated?
have a feedback mechanism in place
to ensure continuous quality
99 (18.1)
209 (38.2) 73 (13.3)
61 (11.2)
improvement?
Education and training
Is it required that the primary person(s) responsible for data entry have…
achieved a minimum level of
269 (49.2) 113 (20.7) 49 (9.0)
18 (3.3)
education
a minimum level of experience
207 (37.8) 164 (30.0) 54 (9.9)
21 (3.8)
training/development devoted to data
240 (43.9) 135 (24.7) 57 (10.4)
15 (2.7)
quality
Is it required that the primary person(s) responsible for monitoring the data have…
achieved a minimum level of
268 (49.0) 68 (12.4)
66 (12.1)
34 (6.2)
education
a minimum level of experience
209 (38.2) 114 (20.8) 74 (13.5)
37 (6.8)
training/development devoted to data
205 (37.5) 122 (22.3) 72 (13.2)
33 (6.0)
quality
Are the skills and performance of the
person(s) in charge of data monitoring
assessed via periodic onsite evaluations 72 (13.2)
243 (44.4) 76 (13.9)
40 (7.3)
by a third party (e.g. manager) during
monitoring visits?
a Number

3 (6.3)

101 (18.5)
101 (18.5)
105 (19.2)

98 (17.9)
101 (18.5)
100 (18.3)

111 (20.3)
113 (20.7)
115 (21.0)

116 (21.2)

of applications used to store data, n=193
total number of answers for this question is n=48.
Abbreviations: CRF, Case report form; SOP, Standard operating procedure
Statistical techniques: For example, cluster and outlier analyses.
Logic, range and consistency checks: Flag indicator results that fail common-sense comparisons to other indicators or
other disaggregation.
Source data verification: Comparing source data (original or certified copy) documents to data recorded or entered to a
case report form or electronic record or database.
Onsite monitoring: All monitoring activities undertaken at the clinical trial site.
Double data entry: Entering the data twice and comparing differences between datasets
Centralised monitoring: Data collected through an electronic data capture and queries identified by monitor that may
need further attention to alleviate problems.
Remote monitoring: Data monitored off-site, includes delivering documents via email, fax or snail mail to monitoring
personnel to conduct source data verification.
Risked-based targeted monitoring: Focus on certain data points that have been identified to have the most risk.
Risked-based triggered monitoring: After certain events like a large number of adverse events or deviations occur this
leads to more detailed monitoring.
b The

After deletion of 368 cases with missing values, data from 179 clinical studies were available for
regression analysis. 155 clinical studies (86.6%) were classified as an intervention trial. A test of the
full regression model using the forced entry with all 13 predictors against a constant-only model
was not significant, χ2 (13, 179) = 15.827, p=0.259 (Table 4). Multivariate analysis demonstrated
that having a definition for a protocol deviation and/or violation (odds 3.065, p=0.096) was
borderline significant and positively associated with intervention (clinical) trials. None of the other
covariates had a significant association with clinical study classification. The forced entry model
correctly classified the outcome for 87.2% of the cases. Both the forwards χ2 (1, 179) = 3.797,
p=0.051 (Supplementary data 5) and backwards stepwise χ2 (5, 179) = 9.997, p=0.075
(Supplementary data 6) models bordered on significance. However, both models demonstrated that
having a definition for a protocol deviation and/or violation (forward stepwise odds 2.433, p<0.05)
(backward stepwise odds 2.640, p<0.05) had significant, positive association with intervention trial.
The forwards and backwards stepwise models both correctly classified the outcome for 86.6% of
the cases. A higher Nagelkerke R square indicates that the forced entry model (0.155) was a better
model fit, in comparison to the forwards stepwise (0.038) and the backwards stepwise (0.100)
models.

Table 4: Forced entry method, coefficients of the model predicting whether a clinical study was observational or interventional (dependent variable)
based on n=179 (32.7%).
Category
Variable
Univariable analysis
Multivariate analysis
95% CI
χ2*
P
B
Wald
odds
Lower
Upper P
chiratio
square
Phase of study
(4, 373) = 52.930 0.000 a
Trial sitesb
(2, 529) = 1.760 0.415
Participants targeted for baseline enrolmentc
(3, 526) = 5.028 0.170
Clinical study
Participants at baseline P1#
-0.405 0.216
0.667 0.121
3.687 0.642
demographics
Participants at baseline P2#
0.508 0.322
1.663 0.287
9.633 0.571
Participants at baseline P3#
0.120 0.000
1.012 0.125
8.193 0.991
Data monitor
(1, 505) = 0.027 0.870
Health centre
(1, 527) = 0.222 0.638
Hospital
(1, 527) = 9.859 0.002 0.185 0.099
1.204 0.379
3.821 0.753
Independent institute
(1, 527) = 0.618 0.432
In home care
(1, 527) = 0.711 0.399a
Data collection
Private practice
(1, 527) = 0.905 0.341
setting
0.002 1.719 2.352
5.581 0.620
50.24 0.125
University
(1, 527) = 9.776
8
0.003 1.426 1.515
4.161 0.430
40.27 0.218
Other
(1, 527) = 8.708
6
Data dictionary
(1, 452) = 0.002 0.968
Develop CRFs
(2, 500) = 0.906 0.636
0.047 1.120 2.773
3.065 0.820
11.45 0.096
Definition protocol deviation and/or violation
(1, 466) = 3.950
8
Study set up
Data quality monitoring plan/SOP QA and QC (1, 479) = 2.437 0.119 0.452 0.438
1.571 0.412
5.987 0.508
Outsource data monitoring
(1, 481) = 5.118 0.024a
Follow guidelines/regulations
(1, 467) = 3.031 0.082 -0.293 0.198
0.746 0.206
2.706 0.656
SOP for data collection
(1, 484) = 0.625 0.429
Overcome missing values
(1, 395) = 0.960 0.327
Data collection
Data capture instruments to record source datad (3, 508) = 3.751 0.290
and storage
Data management storage tool used
(1, 447) = 0.423 0.515

Data monitoring
method(s)

Data
representation

Logic, range and consistency checks
Double data entry
Statistical techniques
Risk-based targeted monitoring
Risk-based triggered monitoring
Remote monitoring
Centralised monitoring
Onsite monitoring
Source data verification
Error acceptance level
Standard equation/method to calculate error
Generate data quality and consistency reports
A feedback mechanism CQI

(1, 425) = 0.029
(1, 414) = 0.040
(1, 422) = 0.394
(1, 305) = 0.144
(1, 300) = 3.114
(1, 344) = 2.372
(1, 350) = 1.535
(1, 407) = 1.358
(1, 406) = 2.294
(1, 270) = 0.876
(1, 269) = 0.023
(1, 301) = 0.718
(1, 308) = 2.365

0.865
0.841
0.530
0.705
0.078
0.123
0.215
0.244
0.130
0.349
0.880
0.397
0.124

0.209
-0.239

0.066
0.121

1.233
0.788

0.251
0.205

6.063
3.027

0.797
0.728

-0.426

0.542

0.653

0.210

2.030

0.462

-0.567

0.901

0.567

0.176

1.829

0.342

R2 = .911 (Hosmer & Lemeshow) .085 (Cox & Snell) .155 (Nagelkerke). Model χ 2 (13, 179) = 15.827, p=0.259. Correctly classified 87.2% of the cases.
Abbreviations: CI, confidence interval; CQI, continuous quality improvement; SOP, Standard Operating Procedure; QA, quality assurance; QC, quality control.
* χ2 (df, n)
a 1 cell has an expected count less than 5, therefore excluded.
b Category of trial sites: 1 site, n=296; 2-4 sites, n=116; >5 sites, n=117.
c Category by number of participants enrolled in baseline study: <20 participants, n=49; 20-99 participants, n=192; 100-499 participants, n=203; >500 participants, n=82.
d Number of data capture instruments to record source data category: 1 instrument, n=254; 2 instruments, n=149; 3 instruments, n=68 4+ instruments, n=37.
Participants at baseline uses <20 participants as the referent category. #Participants at baseline P1 (20-99), P2 (100-499), P3 (>500). All other variables are compared with ‘no’ as the
referent category.
Independent variables included in multivariate analysis: clinical study demographics (Participants targeted for baseline enrolment); data collection setting (hospital, university and
other); study set-up (definition for a protocol deviation and/or violation, data quality monitoring plan/SOP QA and QC and follow guidelines/regulations); Data monitoring methods
(risk-based triggered monitoring, remote monitoring and source data verification); and data representation (a feedback mechanism CQI).

4. Discussion
In this Australian national survey, we found that clinical studies implemented various procedures to
ensure data quality; however, not all clinical studies followed International or National guidelines to
ensure data integrity. A borderline association between the data quality monitoring variable, a
definition for protocol deviation and/or violation and intervention trials, may suggest that clinical
studies were more likely to implement the required procedures when they were provided with
additional guidance and resources. Additionally, we saw that technology has modified study
processes in data collection and storage, and implementing ‘new’ monitoring methods. Although
smaller, single-site clinical studies, are yet to adopt technology. These observations suggest that
further education and training are required to implement standardised procedures to guide data
quality in smaller-scale clinical studies.

Approximately 50% of the survey respondents were not following GCP guidelines for monitoring
data quality. This may suggest that GCP may not be explicit enough to ensure data integrity is
followed in all clinical research settings. As the GCP guidelines were written predominantly for
drug intervention trials[40, 41], there might be limitation for their applicability to all clinical
studies. Another reason might be that the majority of survey respondents were from smaller, singlesite research studies with limited resources. This suggests that GCP needs to provide more
accessible information that are tailored for the needs of all clinical research studies including nondrug intervention trials, cohort and observational studies.

Further, this study identified that GCP training was only provided to 45% of data entry staff and
51% of the primary person(s) responsible for monitoring data quality. This number is far behind the
recommendation of a recent working group who concluded GCP training should be provided to all
study personal engaged in the design, conduct, performance, monitoring, auditing, recording,
analysis or reporting of a clinical trial2 [42]. Despite this recommendation, there was a strong
consensus that GCP training lacks relevance to behavioural intervention studies, which may also
explain the observed low GCP training rate for those single site, non-drug intervention trials in this
study. Another explanation may be that in Australia it is recommended if there is inconsistency
between GCP and the National Statement on Ethical Conduct in Human Research (National
Statement), the National statement takes precedence[43].

Clinical trial as defined by the National institute of Health (NIH): A research study in which one or more human
subject are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate
the effects of those interventions on health-related biomedical or behavioural outcomes.
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With additional guidance and resources, it appears that clinical studies are more likely to implement
the required procedures. This observation is supported by the borderline association (forced entry)
between a definition for protocol deviation and/or violation and intervention trials. This is further
supported by both of the stepwise models demonstrating that having a definition for a protocol
deviation and/or violation had a significant, positive association with the intervention trial. This
association was found in all three models and may result from a level of compliance with the
CONSORT statement that recommends reporting protocol violations[44, 45] and the National
Statement which recognises that sponsors, investigators/researchers, institutions and Human
Research Ethics Committees (HRECs) all have responsibilities to monitor clinical trials[46].
Further, supplementary guidance is provided in a reporting framework for protocol deviations3,
‘Reporting of Serious Breaches of Good Clinical Practice (GCP) or the Protocol for Trials
Involving Therapeutic Goods’ which provides definitions, reporting procedures and timeframe,
deviation examples, form templates and general question and answers[47]. Supplementary guidance
has been provided for protocol deviations, which may explain the reason for the association, albeit
the limited compliance with other areas related to monitoring the quality of clinical studies. For
example, a review of 80 clinical trials found that protocol deviations are underreported and larger
clinical trials (larger number of patients, sites, longer duration, complex management structure)
were more likely to report protocol deviations than smaller clinical trials[48]. These findings may
suggest that larger trials have better management and improved facilities, thus are more likely to
report protocol deviations and/or violations. The findings of the review and the current study both
suggest that when greater guidance and resources are provided, clinical studies are more likely to
implement necessary procedures to ensure accurate, reliable and credible data. Therefore, we
advocate eliminating disparity in resources and providing clinical studies in all size and study type
with equal access to freely available standard procedures and clear frameworks. One such data
quality monitoring framework (DQMF) that provides additional guidance and resources has been
proposed by our study team, which is reported elsewhere[49]. In brief, the DQFM was developed
from a small feasibility study (n=20)[5] and draws on the published literature, disregarding
procedures widely applied first-hand in clinical studies. The DQMF requires further development
and empirical testing before it can be recommended for future adaptation and use in clinical studies.
The findings of this national survey are a key step in further developing the DQMF by identifying
common and practical data collection processes, data processing and handling tools and procedures
implemented in clinical research studies.

The term deviation (recommended by ICH E3 – Structure and Content of the Clinical Study Report 2012) has been
used to describe any breach, divergence or departure from the requirement of Good Clinical Practice or the clinical trial
protocol, whether minor or major.
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Although technology plays a key role in improving processes and efficiency in clinical studies,
smaller, single-site clinical studies are yet to adopt technology, as 46% of the respondents in this
survey reported they do not use data management software. A possible explanation for this is that
small, single-site studies find it difficult to afford expensive and sophisticated technology despite
the potential benefit of facilitating critical-decision making procedures[50]. This is in line with the
literature that reported due to the limitation of time and resources, not all research trials implement
the necessary data quality management tools and procedures[16]. Further, evidence suggests that
the adoption of e-technology (digital and electronic technology that utilizes mobile devices or the
Internet) into the design of clinical research studies has been relatively slow due to limited
empirical evidence to support the benefits of such technology in improving study design and
results[51]. Instead, this study revealed clinical studies implemented ‘traditional methods’ which
included paper data capture and SDV. In accordance with this finding, a previous Canadian survey
also reported that 59% of the clinical trials used paper CRFs and reported advantages such as quick
to implement, simple and convenient[52]. It is clear that traditional methods implemented to collect
and monitor data are still being used despite updated published evidence that promotes ‘new’
methods which compliment trial procedures by improving the resources available[53-55]. The
results of this survey need to be interpreted with caution as we did not specifically ask respondents
to point out the difference between automatic and manual data capture to record study events. With
automatic capture a machine reads the paper which may reduce the amount of overall error in
clinical studies. Currently, there is lack of coherent guidance and standard “good practices” in
clinical research. Paper data collection and transcription of data into an electronic system are more
likely to introduce avenues for error, is a costly and an onerous procedure[56]. Similarly, two
reviews on monitoring methods, found SDV to be time consuming, expensive and does not
guarantee error free results[53, 57]. To overcome this issue standard procedures and education are
needed on the benefits of incorporating technology into clinical studies to improve research
outcomes.

There are several limitations in this study. First, the majority of responders were from small, singlesite academic studies, causing limitation on representativeness of the results for the broader research
community including substantial number of multi-site international clinical trials. An additional
restriction is that our survey respondents were all associated to clinical studies listed on the
ANZCTR database as ‘recruiting' or ‘active, not recruiting’, in which the ANZCTR accounts for
approximately 60% of registered clinical studies in Australia [58]. Another limitation is that the
respondents were identified from a Clinical Trials Registry by Australian postal address. The same

contact person could be contacted repeatedly due to being listed more than once via multiple
associations with the Registry. This could have a negative or positive impact on response rates.
Survey results are subject to potential bias in a positive direction as the respondents who completed
the survey may be more knowledgeable about data quality monitoring measures and procedures
than those who were non-respondents. Furthermore, the number of non-respondents might be due to
confidentiality considerations[59]. Although we attempted to calculate the total number of ‘return to
sender’ letters and bounced emails, these numbers should be considered with caution. It should be
highlighted that throughout this research we have referred to clinical research as it is mostly
concerned with prospective clinical studies, though we note that clinical studies may also include
retrospective observational studies. While we did ask respondents about the study type, we did not
explicitly ask them about their study designs. We did not attempt to sample evenly by clinical study
type and, therefore, our results sway towards 83% of respondents reporting for an intervention trial.
However, this figure is similar with the national figure of, 86% of registered clinical studies were
intervention trials between 2006 – 15[58]. Thus, the results of our study may be considered
representative of Australian clinical studies. The logistic regression output should be interpreted
with caution as it was derived from a limited 24 observational studies that were included in the
analysis. Finally, as with any survey, the results are subject to recall bias.

Our findings enable us to make recommendations for future research. First, understanding the
reason why clinical studies are not following national and international guidelines using qualitative
methods. Secondly, further guidance is warranted to provide detailed frameworks which include
resources for clinical study monitoring best practice. Thirdly, the use of technology to improve
study procedures needs more empirical evidence to guide clinical researcher choice in overcoming
challenges related to data collection, monitoring and upholding quality.

The evidence of this study enables us to hypothesise the reasons and challenges as to why smaller,
single-site clinical studies are not using current guidance and technology for data monitoring. We
speculate that the major challenges are limited resources, facilities, management and funding. As
suggested by Eisenstein et al.[60] the financial cost of monitoring site data is estimated to represent
25-30% of the total study costs. This evaluation is based on two randomised phase III multinational
drug trials which called for >14000 patients. Therefore, a different evaluation for small single-site
clinical studies is required and may result in different percentage costs. One consideration for small
scale clinical studies is to use freely available electronic software or web-based applications for data
capture and management. The two primary data management tools used by our survey respondents
were REDCap[27] and OpenClinica (www.OpenClinica.com). Both of these tools provide easy to

use electronic data capture (EDC) systems with built-in data validation (logic, range and
consistency checks), data tracking (audit trails), automated export procedures for statistical analysis
and the availability to import data from external sources. There are multiple alternative EDC
systems that are not named here. However, clinical researchers need to consider the additional costs
that the freely available open source software may incur with regard to staff training, maintenance,
support and hardware to operate the system. We suggest researchers evaluate the available software
options and compare them with their intended goals and requirements to make an informed decision
as to which software system is most suitable for their study.

From our findings we also suggest that clinical studies develop a data management plan, a risk and
safety management plan and a monitoring plan as previous research suggests that data management
plans are not necessarily utilised in all cases due to reasons that include sponsor requirements and
monetary constraints[5, 9, 50]. The monitoring plan should explicitly define the approach for data
definition, collection, processing and handling, and clearly describe the education and training
related to data quality that staff undertake. Sharing these plans between small, single-site academic
studies will enable knowledge sharing between clinical study sites and provide additional guidance
on any challenges or reasons why procedures worked or did not work. This could be supported by
an online standardised platform which provides generic and baseline templates which are available
for download by clinical researchers, to share and integrate procedures efficiently between
organisations and groups. Though current practice suggests that research groups may not be willing
to share their data quality procedures as they may be considered confidential by many
organisations[59]. To provide greater motivation to developing data management plans as core to
clinical research, the use of incentives (e.g. career development and training) may be used as a
strategy to improve staff self-awareness and engagement in their commitment to maintaining data
quality[61]. Finally, until a more suitable education and training course for non-drug intervention
trials is developed, we recommend that all clinical studies complete the GCP education and training
as it remains the international ‘gold standard’.

5. Conclusion
In summary, we found that not all Australian clinical studies follow the GCP guidelines and the
majority of study personnel do not receive GCP training. Instead, small, single-site academic
clinical studies implement various non-standardised ad hoc measures and procedures to ensure data
quality. When provided with additional guidance, resources and frameworks, clinical studies were
more likely to implement the necessary procedures. Small, single-site academic studies are yet to
adopt technology to replace their use of traditional methods to collect and monitoring data, which

are costly and burdensome. In order to improve standardisation of clinical trials, education and
training needs to be provided and accessible to all researchers in all types of clinical studies, large
and small.
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Figure legends
Figure 1 – Survey invitation flow diagram.

Table legends
Table 1 – Survey respondents demographic characteristics (n=547).
Table 2 – Survey respondents associated clinical study demographic characteristics (n=547).
Table 3 – Data quality monitoring, education and training on data quality (n=547).
Table 4 – Forced entry method, coefficients of the model predicting whether a clinical study was
observational or interventional based on n=179 (32.7%).
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Supplementary data 1
Table 1: Combined ‘Yes’ and ‘Don’t know’ responses for national and international regulations,
guidelines and/or standards item (n=422).
Variable
Percent of
n (%)
Cases (%)
Which of the following regulations, guidelines and/or standards are followed.a,b
National Statement on Ethical Conduct and Research
363 (40.2)
86.0
Good Clinical Practice Guidelines (GCP) - International
230 (25.4)
54.5
Conference for Harmonisation
The Australian Clinical Trial Handbook - Therapeutic Goods
142 (15.7)
33.6
Administration (TGA)
International classification of diseases (ICD)
41 (4.5)
9.7
International Standards Organisation (ISO) quality systems
24 (2.7)
5.7
standard
Food and Drug Authority (FDA) 21 CRF part 11
12 (1.3)
2.8
Systematized Nomenclature of Medicine -- Clinical Terms
11 (1.2)
2.6
(SNOMED-CT)
Clinical data acquisition standards harmonization (CDASH)
10 (1.1)
2.4
Food and Drug Authority (FDA) Monitoring of Clinical
8 (0.9)
1.9
Investigations
Operational Data Model (ODM)
6 (0.7)
1.4
Analysis Data Model (ADaM)
3 (0.3)
0.7
Study data tabulation model implementation guide for human
2 (0.2)
0.5
clinical trials (SDTM)
Health Level 7 (HL7)
1 (0.1)
0.2
Logical Observation Identifiers names and Codes (LOINC)
1 (0.1)
0.2
Other
23 (2.5)
5.5
Don’t know
22 (2.4)
5.2
Missing
4 (0.4)
0.9
a Multiple response question (select all that apply)
b Total n (%)=903 (100.0)

Supplementary data 2
Table 1: Data collection and storage tools (n=547)
Variable

n (%)

Percent of
Cases (%)

Which data capture instruments are used to record source data? a,b
Paper
391 (41.2)
77.0
Microsoft excel spreadsheet/workbook
140 (14.7)
27.6
Database management software /tool
114 (12.0)
22.4
Electronic case report form (eCRF)
91 (9.6)
17.9
Automated instrument
84 (8.8)
16.5
(e.g. pathology, ultrasound, x-ray)
Mobile or tablet application
53 (5.6)
10.4
Don’t know
3 (0.3)
0.6
Other
35 (3.7)
6.9
Missing
39 (4.1)
7.1
Are any of the following clinical data management tools used to store data? a,c
Noned
256 (45.7)
51.7
REDCap
87 (15.5)
17.6
OpenClinica
13 (2.3)
2.6
RAVE
6 (1.1)
1.2
ORACLE CLINICAL
4 (0.7)
0.8
MACRO
1 (0.2)
0.2
Not applicable
26 (4.6)
5.3
Don’t know
22 (3.9)
4.4
Other
93 (16.6)
18.8
Missing
52 (9.3)
9.5
a Multiple response question (select all that apply)
b Total n (%)=950 (100.0)
c Total n (%)=560 (100.0)
d n=2 respondents answered ‘no’ and ‘not applicable’ due to select all apply survey item. Responses
to ‘no’ have been excluded from Table 3 and therefore n=254.

Supplementary data 3
Table 3: Who reviews the reports of data quality and consistency (n=72).
Variable
Who reviews the reports of data quality and consistency? a,b
Chief investigator
Senior staff management
Data entry staff
Auditor/Monitor
Sponsor
Other
Missing
a Multiple response question (select all that apply)
b Total n (%)=148 (100.0)

n (%)
46 (31.1)
36 (24.3)
31 (20.9)
15 (10.1)
9 (6.1)
11 (7.4)
0 (0)

Percent of
Cases (%)
63.9
50.0
43.1
20.8
12.5
15.3
0

Supplementary data 4
Table 1: Follow-up questions for education and training data entry staff (n=240) and data monitor
(n=205).
Is it required that the primary person(s) responsible for data entry have training/development
devoted to data quality.
If yes, which of the following areas are data entry staff
Percent of
n (%)
provided training in:a,b
Cases (%)
Protocol procedure
181 (22.2)
79.1
SOPs
150 (18.4)
63.0
skills development
136 (16.7)
57.1
specific research are investigation
116 (14.2)
48.7
Monitoring process
111 (13.6)
46.6
ICH-GCP
106 (13.0)
44.5
Don’t know
5 (0.6)
2.1
Other
9 (1.1)
3.8
Missing
2 (0.2)
0.8
If yes, please specify how education and training is
delivered:a,c
one-on-one
175 (44.5)
74.5
Group
116 (29.5)
49.4
online/computer modules(s)
91 (23.2)
38.7
Other
6 (1.5)
2.6
Missing
5 (1.3)
2.1
If yes, please specify when education and training is
delivered:a,d
Prior to research
199 (44.0)
85.0
Throughout
169 (37.4)
72.2
Triggered due to reoccurring event (e.g. incomplete
31.6
74 (16.4)
CRFs)
Other
4 (0.9)
1.7
Missing
6 (1.3)
2.5
Is it required that the primary person(s) responsible for monitoring the data have
training/development devoted to data quality.
If yes, which of the following areas is this person provided training in:a,e
Protocol procedure
164 (20.6)
80.8
Monitoring process
152 (19.1)
74.9
skills development
127 (16.0)
62.2
SOPs
126 (15.8)
62.1
specific research are investigation
113 (14.2)
55.7
ICH-GCP
104 (13.1)
51.2
Don’t know
2 (0.3)
1.0
Other
5 (0.6)
2.5
Missing
2 (0.3)
1.0
If yes, please specify how education and training is delivered:a,f
one-on-one
147 (41.5)
74.2
online/computer modules(s)
96 (27.1)
48.5
Group
94 (26.6)
47.5
Other
10 (2.8)
5.1
Missing
7 (2.0)
3.4
If yes, please specify when education and training is delivered:a,g
Prior to research
168 (45.0)
83.6

Throughout
Triggered due to reoccurring event (e.g. incomplete CRFs)
Other
Missing
a Multiple

response question (select all that apply)
(%)=816 (100.0)
c Total n (%)=393 (100.0)
d Total n (%)=452 (100.0)
e Total n (%)=795 (100.0)
f Total n (%)= 354 (100.0)
g Total n (%)=373 (100.0)
b Total n

139 (37.3)
57 (15.3)
5 (1.3)
4 (1.1)

69.2
28.4
2.5
2.0

Supplementary data 5
Table 1: Forward stepwise (step 1), coefficients of the model predicting whether a clinical study was observational or interventional (dependent
variable) based on n=179 (32.7%).
Category

Variable
B

Study set up

Definition protocol deviation and/or violation

0.889

Multivariate analysis
95% CI
Wald chiodds
Lower
Upper
square
ratio
3.922
2.433 1.009
5.864

P
0.048

R2 = .0 (Hosmer & Lemeshow) .021 (Cox & Snell) .038 (Nagelkerke). Model χ 2 (1, 179) = 3.797, p=0.051. Correctly classified 86.6% of the cases.
Abbreviations: CI, confidence interval.
Definition for protocol deviation and/or violation is compared with ‘no’ as the referent category.
Independent variables included in multivariate analysis: clinical study demographics (Participants targeted for baseline enrolment); data collection setting (hospital, university
and other); study set-up (definition for a protocol deviation and/or violation, data quality monitoring plan/SOP QA and QC and follow guidelines/regulations); Data
monitoring methods (risk-based triggered monitoring, remote monitoring and source data verification); and data representation (a feedback mechanism CQI).

Supplementary data 6
Table 1: Backwards stepwise (step 9), coefficients of the model predicting whether a clinical study was observational or interventional
(dependent variable) based on n=179 (32.7%).
Category

Variable
B

Data collection
setting
Study set up

University
Other
Definition protocol deviation and/or violation

1.674
1.472
0.971

Multivariate analysis
95% CI
Wald chiodds
Lower
Upper
square
ratio
2.511
5.332 0.673
42.264
1.943
4.356 0.550
34.503
4.469
2.640 1.073
6.495

P
0.113
0.163
0.035

R2 = .417 (Hosmer & Lemeshow) .054 (Cox & Snell) .100 (Nagelkerke). Model χ 2 (5, 179) = 9.997, p=0.075. Correctly classified 86.6% of the cases.
Abbreviations: CI, confidence interval.
All variables (university setting, other setting, definition for protocol deviation and/or violation) are compared with ‘no’ as the referent category.
Independent variables included in multivariate analysis: clinical study demographics (Participants targeted for baseline enrolment); data collection setting (hospital, university
and other); study set-up (definition for a protocol deviation and/or violation, data quality monitoring plan/SOP QA and QC and follow guidelines/regulations); Data
monitoring methods (risk-based triggered monitoring, remote monitoring and source data verification); and data representation (a feedback mechanism CQI).

